Abstract

Nephrolithiasis is a highly prevalent disease worldwide with a high level of acute and chronic morbidity. First-line treatment is typically analgesia with non-steroid anti-inflammatory drugs until the stone passes, otherwise urological intervention may be necessary. Certain medications such as alpha blockers and nonsteroidal anti-inflammatory drugs, corticosteroids, or antispasmodics are sometimes used to create passage of stones in order to avoid further urologic intervention or hospitalization. However, the study results have limited their use and meanwhile major adverse events defined as orthostatic hypotension, collapse, syncope, palpitations, or tachycardia have been reported. At the present global circumstances, the SARS-CoV-2 pandemic (COVID-19) has caused widespread disruption of routine surgical care and forced every surgeon to make triage decisions requiring greater ethical and community health consideration. It is necessary to balance the surgical risks and benefits and the medical risks of any perceived delay in treatment, and potential exposure of health care workers and/or patients to the deadly virus.